HMOX1 and breast cancer: This finding not only provides a mechanistic insight into the oncogenic role of ROS–NRF2–HO-1 in DPP-4i-driven BC progression but also offers novel insights relevant for the development of effective immunotherapeutic approaches to alleviate the dark side of DPP-4i in BC progress.